Abbott Laboratories banner

Abbott Laboratories
XBER:ABL

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
XBER:ABL
Watchlist
Price: 105.82 EUR Market Closed
Market Cap: €187.1B

EV/S

3.5
Current
27%
Cheaper
vs 3-y average of 4.8

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
3.5
=
Enterprise Value
€166.8B
/
Revenue
$45.1B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
3.5
=
Enterprise Value
€166.8B
/
Revenue
$45.1B

Valuation Scenarios

Abbott Laboratories is trading below its 3-year average

If EV/S returns to its 3-Year Average (4.8), the stock would be worth €144.86 (37% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-41%
Maximum Upside
+37%
Average Upside
5%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 3.5 €105.82
0%
3-Year Average 4.8 €144.86
+37%
5-Year Average 4.8 €144.68
+37%
Industry Average 2.1 €62.12
-41%
Country Average 3 €91.29
-14%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
€166.8B
/
Apr 2026
$45.1B
=
3.5
Current
€166.8B
/
Dec 2026
$49.1B
=
3.4
Forward
€166.8B
/
Dec 2027
$53.1B
=
3.1
Forward
€166.8B
/
Dec 2028
$56.7B
=
2.9
Forward
€166.8B
/
Dec 2029
$63.2B
=
2.6
Forward
€166.8B
/
Dec 2030
$67.6B
=
2.5
Forward
€166.8B
/
Dec 2031
$74.4B
=
2.2
Forward
€166.8B
/
Dec 2032
$79.6B
=
2.1
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close

Market Distribution

In line with most companies in the United States of America
Percentile
62nd
Based on 11 256 companies
62nd percentile
4.2
Low
0 — 1.6
Typical Range
1.6 — 5.3
High
5.3 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.6
Median 3
70th Percentile 5.3
Max 4 613 320.1

Abbott Laboratories
Glance View

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABL Intrinsic Value
99.16 EUR
Overvaluation 6%
Intrinsic Value
Price €105.82
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett